In clinical studies, complementary treatment with IgE monoclonal antibodies was clinically effective, with a favorable safety profile, in patients with severe asthma [9,26], chronic urticaria [27,28,29], and, more recently, in patients with chronic rhinosinusitis with nasal polyposis [30]. This evidence concerns the gene IGHE and asthma.